CoChat
Sign Up
Cited by 114Psychedelics and Drug StudiesTreatment of Major DepressionBipolar Disorder and Treatment

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial

Open access
Aaronson, Scott T., van der Vaart, Andrew, Miller, Tammy, LaPratt, Jeffrey, Swartz, Kimberly, Shoultz, Audrey, Lauterbach, Margo, Sackeim, Harold A., Suppes, Trisha·2024·JAMA Psychiatry
DOI 10.1001/jamapsychiatry.2023.4685
Open this paper in CoChat — free accountOpen PDF

Abstract

Importance: Bipolar II disorder (BDII) is a debilitating condition frequently associated with difficult-to-treat depressive episodes. Psilocybin has evidence for rapid-acting antidepressant effects but has not been investigated in bipolar depression. Objective: To establish the safety and efficacy of psilocybin in patients with BDII in a current depressive episode. Design, Setting, and Participants: This was a 12-week, open-label nonrandomized open-label trial conducted at Sheppard Pratt Hospital. Participants aged 18 to 65 years with BDII, a current depressive episode longer than 3 months, and documented insufficient benefit with at least 2 pharmacologic treatments during the current episode were invited to participate. Of 70 approached, 19 met inclusion criteria and were enrolled. The trial was conducted between April 14, 2021, and January 5, 2023. Interventions: A single dose of synthetic psilocybin, 25 mg, was administered. Psychotropic medications were discontinued at least 2 weeks prior to dosing. Therapists met with patients for 3 sessions during pretreatment, during the 8-hour dosing day, and for 3 integration sessions posttreatment. Main Outcomes and Measures: The primary outcome measure was change in Montgomery-Åsberg Depression Rating scale (MADRS) at 3 weeks posttreatment. Secondary measures included MADRS scores 12 weeks posttreatment, the self-rated Quick Inventory of Depression Symptoms-Self Rating (QIDS-SR), and the self-rated Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF), each completed at baseline and all subsequent visits. Safety measures included the Columbia Suicide Severity Rating Scale (CSSRS) and the Young Mania Rating Scale (YMRS) completed at each visit. Results: Of the 15 participants in this study (6 male and 9 female; mean [SD] age, 37.8 [11.6] years), all had lower scores at week 3, with a mean (SD) change of −24.00 (9.23) points on the MADRS, (Cohen d = 4.08; 95% CI, −29.11 to −18.89; P < .001). Repeat measures analysis of variance showed lower MADRS scores at all tested posttreatment time points, including the end point (Cohen d = 3.39; 95% CI, −33.19 to −16.95; adjusted P < .001). At week 3, 12 participants met the response criterion (50% decrease in MADRS), and 11 met remission criterion (MADRS score ≤10). At the study end point, 12 patients met both response and remission criteria. QIDS-SR scores and Q-LES-Q-SF scores demonstrated similar improvements. YMRS and CSSRS scores did not change significantly at posttreatment compared to baseline. Conclusions and Relevance: The findings in this open-label nonrandomized open-label trial suggest efficacy and safety of psilocybin with psychotherapy in BDII depression and supports further study of psychedelics in this population.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamapsychiatry.2023.4685

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 34 references

Research works printed but not linked: 1

  1. Sheehan, 2016, The Mini International Neuropsychiatric Interview (Version 7.0. 2) for DSM-5

Cited by

Sorted by citations

Items 101–114 of 114

Related

See all

Metadata

Authors
Aaronson, S. T., van der Vaart, A., Miller, T., LaPratt, J., Swartz, K., Shoultz, A., Lauterbach, M., Sackeim, H. A., & Suppes, T.
Affiliations
  • University of Maryland, Baltimore (US)
  • Department of Psychiatry, University of Maryland, Baltimore
  • Sheppard Pratt Health System (US)
  • Department of Psychiatry, Columbia University, New York
  • VA Palo Alto Health Care System (US)
Corresponding author
Aaronson, Scott T.
ORCID
Venue
JAMA Psychiatry
Publisher
American Medical Association (AMA)
Published
2024-06-01
Volume
81
Issue
6
Pages
555
ISSN
2168-622X (ISSN-L)
DOI
10.1001/jamapsychiatry.2023.4685
OpenAlex
W4389397550
Cited by
114
References
34
Citations by year
2026: 36 · 2025: 44 · 2024: 33
FWCI
33.10
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • JAMA Psychiatry (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords
psilocybin, bipolar II disorder, bipolar depression, treatment-resistant depression, psychedelic-assisted psychotherapy, depression severity, suicide risk, mania, quality of life, safety and tolerability, Montgomery-Asberg Depression Rating Scale, Young Mania Rating Scale
MeSH terms
Adult, Bipolar Disorder, Combined Modality Therapy, Major Depressive Disorder, Female, Hallucinogens, Humans, Male, Middle Aged, Psilocybin, Psychotherapy, Treatment Outcome, Young Adult, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review